8-K: Axogen Q3 Revenue Jumps 23.5%, Raises Full-Year Guidance

Axogen, Inc. reported strong third-quarter 2025 financial results with a 23.5% revenue increase and raised its full-year revenue guidance to at least 19% growth.

Summary

• Third quarter 2025 revenue was $60.1 million, a 23.5% increase compared to Q3 2024, and a 6.0% increase over Q2 2025.
• Gross margin for Q3 2025 was 76.6%, up from 74.9% in Q3 2024 and 74.2% in Q2 2025.
• Net income for the quarter was $0.7 million, or $0.01 per share, compared to a net loss of $1.9 million, or $0.04 per share, in Q3 2024.
• Adjusted net income was $6.1 million, or $0.12 per share, up from $3.1 million, or $0.07 per share, in Q3 2024.
• Adjusted EBITDA was $9.2 million, compared to $6.5 million for Q3 2024.
• Cash and cash equivalents, restricted cash, and investments totaled $39.8 million at September 30, 2025, an increase of $0.3 million from December 31, 2024, and $3.9 million during Q3 2025.
• Full-year 2025 revenue guidance raised to at least 19% growth, or $222.8 million.
• FDA approval for Avance Nerve Graft BLA is now anticipated by December 5, 2025, extended from September 5, 2025.
• AAHS, ASRM, and AAOMS have released position statements or guidelines recognizing nerve allografts as standard medical practice.
• Expanded coverage and reimbursement for nerve repair increased new covered lives by approximately 1.1 million in Q3, totaling 18.1 million new lives in 2025, bringing commercial payer coverage to over 64%.

Sentiment

Score: 8

Explanation: Strong financial performance with significant revenue growth, a return to net income, and increased adjusted EBITDA. The raised full-year guidance and positive market development milestones (professional society endorsements, expanded coverage) are highly positive. The BLA delay is a minor setback but approval is still anticipated within the year, and the company expects to be net cash flow positive for the full year.

Positives

• Revenue increased by 23.5% year-over-year to $60.1 million in Q3 2025.
• Gross margin improved to 76.6% in Q3 2025 from 74.9% in Q3 2024.
• Achieved net income of $0.7 million ($0.01 per share) in Q3 2025, reversing a net loss of $1.9 million ($0.04 per share) in Q3 2024.
• Adjusted net income more than doubled to $6.1 million ($0.12 per share) in Q3 2025 from $3.1 million ($0.07 per share) in Q3 2024.
• Adjusted EBITDA increased to $9.2 million in Q3 2025 from $6.5 million in Q3 2024.
• Cash and investments increased by $3.9 million during Q3 2025, with a total balance of $39.8 million.
• Full-year 2025 revenue guidance was raised to at least 19% growth, or $222.8 million.
• Broad-based double-digit revenue growth across all markets (Extremities, Oral Maxillofacial & Head and Neck, and Breast).
• AAHS and ASRM released official position statements recognizing nerve allograft as a standard medical practice option, adding to AAOMS guidelines.
• Expanded coverage and reimbursement added approximately 1.1 million new covered lives in Q3, bringing total new lives in 2025 to 18.1 million and commercial payer coverage to over 64%.
• Strong progress in High Potential (HiPo) accounts, yielding approximately 64% of YoY revenue growth and a 19% YoY increase in average account productivity.
• Exceeded the 2025 target for OMF/H&N surgeons trained (57 trained YTD vs. target 45).

Negatives

• The PDUFA goal date for Avance Nerve Graft BLA approval was extended from September 5, 2025, to December 5, 2025.
• Anticipated Avance Nerve Graft BLA approval is expected to negatively impact gross margin by approximately 1%, or $2 million, due to one-time costs.
• Net loss for the nine months ended September 30, 2025, was $(2.547) million, compared to $(10.414) million for the same period in 2024, still a loss.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(2.226) million.
• Net cash used in investing activities for the nine months ended September 30, 2025, was $(9.359) million.

Risks

• Potential disruptions from leadership transitions.
• Global supply chain issues.
• Record inflation.
• Hospital staffing challenges.
• Product development timelines.
• Product potential.
• Expected clinical enrollment timing and outcomes.
• Regulatory processes and approvals.
• Financial performance.
• Sales growth.
• Surgeon and product adoption rates.
• Market awareness of products.
• Data validation processes.
• Visibility at and sponsorship of conferences and educational events.
• Global business disruption from Russia's invasion of Ukraine and related sanctions.
• Recent geopolitical conflicts in the Middle East.
• Evolving macroeconomic environment (including financial market volatility).
• Escalating geopolitical tensions and trade disputes with U.S. trading partners.
• Potential impact of recent government actions and policies, including the One Big Beautiful Bill Act and the October 2025 U.S. government shutdown, on business, tax position, and regulatory processes.
• Risks detailed under Part I, Item 1A., Risk Factors, in the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The company raised its full-year 2025 revenue guidance to at least 19% growth, targeting $222.8 million. Gross margin for the year is expected to be in the range of 73% to 75%, with an anticipated 1% or $2 million negative impact due to one-time costs related to the Avance Nerve Graft BLA approval. The company reiterates its expectation to be net cash flow positive for the full year. FDA approval for the Avance Nerve Graft BLA is now anticipated by December 5, 2025. The company aims for 100 procedures in its prostate clinical development by year-end.

Management Comments

• "Our third quarter performance reflects the continued maturation of the peripheral nerve repair market, with revenue growing 23.5% to $60.1 million and adjusted EBITDA of $9.2 million as we scale our commercial operations."
• "New position statements from AAHS and ASRM, together with AAOMS guidelines recognizing nerve allografts as standard medical practice, and the addition of 1.1 million additional covered lives, validate our ongoing market development strategy."
• "With double-digit growth across all markets and the expected completion of our Avance Nerve Graft BLA in December, we're advancing our mission to make peripheral nerve repair an expected standard of care."

Industry Context

Axogen operates in the peripheral nerve regeneration and repair market, which is showing signs of maturation. The recognition of nerve allografts as standard medical practice by key professional societies (AAHS, ASRM, AAOMS) signifies a positive shift in clinical acceptance and market development for solutions like Axogen's Avance Nerve Graft. Expanded insurance coverage further supports market penetration. The company's broad-based double-digit growth across multiple surgical markets (Extremities, Oral Maxillofacial & Head and Neck, Breast) indicates strong demand and effective commercial execution within this specialized medical device sector. The ongoing BLA process for Avance Nerve Graft positions Axogen to potentially further solidify its leadership in the biologics segment of nerve repair.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or global benchmarks. It focuses on internal performance metrics and market development within its niche.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, return to profitability, raised revenue guidance, and progress in market development and regulatory approval.
• Patients: Positive impact through expanded recognition of nerve allografts as standard medical practice and increased insurance coverage, potentially leading to broader access to innovative nerve repair solutions.
• Surgeons/Healthcare Providers: Positive impact through increased validation of nerve allografts as standard medical practice and continued professional education and training programs.
• Employees: Positive impact from a growing company with expanding commercial operations and continued investment in clinical development.

Next Steps

• Anticipate FDA approval for Avance Nerve Graft BLA by December 5, 2025.
• Continue scaling commercial operations.
• Advance the mission to make peripheral nerve repair an expected standard of care.
• Achieve the goal of 100 procedures in prostate clinical development by year-end.
• Continue to execute on market development strategies, including professional education and clinical research.

Key Dates

Recommendation

The company demonstrated robust financial performance in Q3 2025, marked by substantial revenue growth (23.5% YoY), a return to net income, and significant increases in adjusted net income and EBITDA. The decision to raise full-year revenue guidance to at least 19% growth, alongside the expectation of being net cash flow positive for the full year, signals strong operational momentum and management confidence. Key market development achievements, such as the recognition of nerve allografts as standard medical practice by leading professional societies and expanded insurance coverage for 18.1 million new lives, significantly de-risk future growth prospects and expand the addressable market. While the FDA BLA approval for Avance Nerve Graft was delayed by three months, it is still anticipated by December 5, 2025, which is a near-term catalyst. The broad-based double-digit growth across all markets further underscores the strength of the product portfolio and commercial execution. These factors collectively point to a company with strong fundamentals, positive catalysts, and a clear path to continued growth and profitability, making it an attractive investment.

Keywords

Peripheral nerve repair, Nerve regeneration, Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, Avive+ Soft Tissue Matrix, Biologics License Application (BLA), FDA approval, Medical devices, Surgical solutions, Biotechnology, Healthcare, Q3 2025 earnings, Financial results, Revenue guidance, Gross margin, Adjusted EBITDA, Peripheral nerve injuries, Neurotization, Allograft, Extracellular matrix (ECM)